Want to see IMCC full AI Analyst Report?
IMCC Stock Chart & Stats
$0.12
-$0.01(-9.02%)
At close: 4:00 PM EDT
$0.12
-$0.01(-9.02%)
Day’s Range― - ―
52-Week Range$0.10 - $3.13
Previous Close$2.49
Volume2.03M
Average Volume (3M)72.27K
Market Cap
$1.04M
Enterprise Value$12.04
Total Cash (Recent Filing)$1.15M
Total Debt (Recent Filing)$14.95M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding9,016,539
10 Day Avg. Volume74,089
30 Day Avg. Volume72,265
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-9.42
Price to Sales (P/S)0.15
P/FCF Ratio1.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$62.75M
Bulls Say, Bears Say
Bulls Say
Dual-market Regulated FootprintMaintaining licensed operations in both Israel and Germany provides durable geographic diversification in tightly regulated medical cannabis markets. This reduces single-market regulatory exposure, spreads operational risk, and enables cross-market learning on compliance and distribution that supports steadier long-term revenue.
Proprietary Patient Data And InsightsOwnership of patient data and analytics supports consistent product quality, targeted assortment and improved patient retention—advantages in prescription-driven markets. These capabilities can strengthen margins and distribution efficiency over time, creating a defensible operational edge versus commodity suppliers.
Improving Gross MarginsA material uplift in gross margin indicates progress on cost control, pricing or product mix, which is a structural lever for moving toward profitability. If sustained, higher gross margins give management room to invest in growth or reduce operating losses without needing equivalent revenue increases.
Bears Say
Negative Stockholders' EquityNegative shareholders' equity is a persistent solvency concern that materially reduces financial flexibility. It can constrain access to financing, complicate counterparty relationships, and signal prior losses that must be absorbed before equity value recovers, raising long-term refinancing and operational risk.
Sustained Operating LossesOngoing operating losses and recent revenue decline show the cost base exceeds current market demand. Persistent deficits erode cash reserves and require repeated financing or structural cost reduction. Without durable revenue growth, losses threaten long-term viability and limit ability to invest in scale or R&D.
Reliance On Equity-linked FinancingsRepeated convertible note financings that convert to shares indicate dependence on equity-linked capital to fund operations. This pattern preserves cash short-term but increases dilution risk and may deter strategic investors. Long-term reliance on such instruments can undermine shareholder value and restrict capital planning.
IM Cannabis Corp News
IMCC FAQ
What was IM Cannabis Corp’s price range in the past 12 months?
IM Cannabis Corp lowest stock price was $0.10 and its highest was $3.13 in the past 12 months.
What is IM Cannabis Corp’s market cap?
IM Cannabis Corp’s market cap is $1.04M.
When is IM Cannabis Corp’s upcoming earnings report date?
IM Cannabis Corp’s upcoming earnings report date is Aug 17, 2026 which is in 10 days.
How were IM Cannabis Corp’s earnings last quarter?
IM Cannabis Corp released its earnings results on May 13, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is IM Cannabis Corp overvalued?
According to Wall Street analysts IM Cannabis Corp’s price is currently Overvalued.
Does IM Cannabis Corp pay dividends?
IM Cannabis Corp does not currently pay dividends.
What is IM Cannabis Corp’s EPS estimate?
IM Cannabis Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IM Cannabis Corp have?
IM Cannabis Corp has 9,016,539 shares outstanding.
What happened to IM Cannabis Corp’s price movement after its last earnings report?
IM Cannabis Corp reported an EPS of -$0.28 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.187%.
Which hedge fund is a major shareholder of IM Cannabis Corp?
Currently, no hedge funds are holding shares in IMCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IM Cannabis Corp
IM Cannabis Corp. specializes in the cultivation, production, and provision of medicinal cannabis goods throughout international markets such as Israel, Germany, and Canada. The company offers a range of cannabis products, including flowers and specifically formulated cannabis extracts, marketed under its IMC brand. Furthermore, it supplies dried flower, pre-rolled products, and compressed hashish via its WAGNERS and Highland Grow labels. IM Cannabis Corp. serves a broad customer base, addressing the needs of both medical patients and adult recreational consumers. Its corporate headquarters are located in Tel Aviv-Yafo, Israel.